| In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics D Zhou, TB Andersson, SW Grimm Drug metabolism and disposition 39 (4), 703-710, 2011 | 174 | 2011 |
| Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions D Zhou, L Afzelius, SW Grimm, TB Andersson, RJ Zauhar, I Zamora Drug metabolism and disposition 34 (6), 976-983, 2006 | 95 | 2006 |
| Ceftazidime‐avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups J Li, M Lovern, ML Green, J Chiu, D Zhou, C Comisar, Y Xiong, J Hing, ... Clinical and Translational Science 12 (2), 151-163, 2019 | 76 | 2019 |
| Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults … TN Johnson, D Zhou, KH Bui Biopharmaceutics & drug disposition 35 (6), 341-352, 2014 | 75 | 2014 |
| Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children W Zhou, TN Johnson, H Xu, SYA Cheung, KH Bui, J Li, N Al‐Huniti, ... CPT: pharmacometrics & systems pharmacology 5 (9), 475-483, 2016 | 66 | 2016 |
| Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children W Zhou, TN Johnson, KH Bui, SYA Cheung, J Li, H Xu, N Al‐Huniti, ... Clinical Pharmacology & Therapeutics 104 (1), 188-200, 2018 | 64 | 2018 |
| Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations V Pilla Reddy, K Bui, G Scarfe, D Zhou, M Learoyd Clinical Pharmacology & Therapeutics 105 (1), 229-241, 2019 | 58 | 2019 |
| Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients JS Bradley, J Armstrong, A Arrieta, R Bishai, S Das, S Delair, T Edeki, ... Antimicrobial agents and chemotherapy 60 (10), 6252-6259, 2016 | 51 | 2016 |
| Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine D Zhou, J Guo, AJ Linnenbach, CL Booth-Genthe, SW Grimm Drug metabolism and disposition 38 (5), 863-870, 2010 | 48 | 2010 |
| Simulation and prediction of the drug‐drug interaction potential of naloxegol by physiologically based pharmacokinetic modeling D Zhou, K Bui, M Sostek, N Al‐Huniti CPT: pharmacometrics & systems pharmacology 5 (5), 250-257, 2016 | 41 | 2016 |
| Evaluation of the drug–drug interaction potential of acalabrutinib and its active metabolite, ACP‐5862, using a physiologically‐based pharmacokinetic modeling approach D Zhou, T Podoll, Y Xu, G Moorthy, K Vishwanathan, J Ware, JG Slatter, ... CPT: pharmacometrics & systems pharmacology 8 (7), 489-499, 2019 | 37 | 2019 |
| A randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly … JFR Robertson, A Evans, S Henschen, CC Kirwan, A Jahan, LM Kenny, ... Clinical Cancer Research 26 (16), 4242-4249, 2020 | 35 | 2020 |
| Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections S Das, J Li, J Iaconis, D Zhou, GG Stone, JL Yan, D Melnick Journal of Antimicrobial Chemotherapy 74 (2), 425-431, 2019 | 35 | 2019 |
| The effect of quinidine, a strong P‐glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol K Bui, F She, D Zhou, K Butler, N Al‐Huniti, M Sostek The Journal of Clinical Pharmacology 56 (4), 497-505, 2016 | 31 | 2016 |
| Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based … L Zhou, P Sharma, KR Yeo, M Higashimori, H Xu, N Al-Huniti, D Zhou European Journal of Pharmaceutical Sciences 139, 105061, 2019 | 30 | 2019 |
| Bridging olaparib capsule and tablet formulations using population pharmacokinetic meta-analysis in oncology patients D Zhou, J Li, K Bui, M Learoyd, A Berges, T Milenkova, N Al-Huniti, ... Clinical pharmacokinetics 58, 615-625, 2019 | 25 | 2019 |
| Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells D Zhou, AJ Linnenbach, R Liu, RA Luzietti, JJ Harris, CL Booth-Genthe, ... Drug metabolism and disposition 38 (7), 1015-1018, 2010 | 23 | 2010 |
| Effects of CYP3A modulators on the pharmacokinetics of naloxegol K Bui, D Zhou, M Sostek, F She, N Al‐Huniti The Journal of Clinical Pharmacology 56 (8), 1019-1027, 2016 | 22 | 2016 |
| Tumor growth dynamic modeling in oncology drug development and regulatory approval: past, present, and future opportunities N Al‐Huniti, Y Feng, J Yu, Z Lu, M Nagase, D Zhou, J Sheng CPT: pharmacometrics & systems pharmacology 9 (8), 419-427, 2020 | 21 | 2020 |
| A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABAA receptor modulator – an in vitro and in vivo comparison D Zhou, M Sunzel, MD Ribadeneira, MA Smith, D Desai, J Lin, SW Grimm British journal of clinical pharmacology 74 (1), 98-108, 2012 | 21 | 2012 |
